Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.

Abstract:

:Neutralizing antibody responses to the surface glycoproteins of enveloped viruses play an important role in immunity. Many of these glycoproteins, including the severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) protein form trimeric units in the membrane of the native virion. There is substantial experimental and pre-clinical evidence showing that the S protein is a promising lead for vaccines and therapeutics. Previously we generated a panel of monoclonal antibodies (mAbs) to whole inactivated SARS-CoV which neutralize the virus in vitro. Here, we define their specificity and affinity, map several of their epitopes and lastly characterise chimeric versions of them. Our data show that the neutralizing mAbs bind to the angiotensin-converting enzyme 2 (ACE2) receptor-binding domain (RBD) of the SARS S protein. Three of the chimeric mAbs retain their binding specificity while one conformational mAb, F26G19, lost its ability to bind the S protein despite high level expression. The affinity for recombinant S is maintained in all of the functional chimeric versions of the parental mAbs. Both parental mAb F26G18 and the chimeric version neutralize the TO R2 strain of SARS-CoV with essentially identical titres (2.07 and 2.47 nM, respectively). Lastly, a comparison with other neutralizing mAbs to SARS-CoV clearly shows that the dominance of a 33 amino acid residue loop of the SARS-CoV RBD is independent of repertoire, species, quaternary structure, and importantly, the technology used to derive the mAbs. In cases like this, the dominance of a compact RBD antigenic domain and the central role of the S protein in pathogenesis may inherently create immunoselection pressure on viruses to evolve more complex evasion strategies or die out of a host species. The apparent simplicity of the mechanism of SARS-CoV neutralization is in stark contrast to the complexity shown by other enveloped viruses.

journal_name

MAbs

journal_title

mAbs

authors

Berry JD,Hay K,Rini JM,Yu M,Wang L,Plummer FA,Corbett CR,Andonov A

doi

10.4161/mabs.2.1.10788

subject

Has Abstract

pub_date

2010-01-01 00:00:00

pages

53-66

issue

1

eissn

1942-0862

issn

1942-0870

pii

10788

journal_volume

2

pub_type

杂志文章

相关文献

mAbs文献大全
  • Rapid identification of an antibody DNA construct rearrangement sequence variant by mass spectrometry.

    abstract::During cell line development for an IgG1 antibody candidate (mAb1), a C-terminal extension was identified in 2 product candidate clones expressed in CHO-K1 cell line. The extension was initially observed as the presence of anomalous new peaks in these clones after analysis by cation exchange chromatography (CEX-HPLC) ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.36222

    authors: Scott RA,Rogers R,Balland A,Brady LJ

    更新日期:2014-01-01 00:00:00

  • Immunotherapy for Alzheimer disease.

    abstract::Immunotherapy approaches for Alzheimer disease currently are among the leading therapeutic directions for the disease. Active and passive immunotherapy against the beta-amyloid peptides that aggregate and accumulate in the brain of those afflicted by the disease have been shown by numerous groups to reduce plaque path...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.1.2.7829

    authors: Gouras GK

    更新日期:2009-03-01 00:00:00

  • Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

    abstract::The neonatal Fc receptor (FcRn) is important for the metabolic fate of IgG antibodies in vivo. Analysis of the interaction between FcRn and IgG in vitro might provide insight into the structural and functional integrity of therapeutic IgG that may affect pharmacokinetics (PK) in vivo. We developed a standardized pH gr...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.24981

    authors: Schlothauer T,Rueger P,Stracke JO,Hertenberger H,Fingas F,Kling L,Emrich T,Drabner G,Seeber S,Auer J,Koch S,Papadimitriou A

    更新日期:2013-07-01 00:00:00

  • A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions.

    abstract::A mono-specific antibody may recruit a second antigen binding specificity, thus converting to a dual-specific Two-in-One antibody through mutation at the light chain complementarity-determining regions (CDRs). It is, however, unknown whether mutation at the heavy chain CDRs may evolve such dual specificity. Herein, we...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28483

    authors: Lee CV,Koenig P,Fuh G

    更新日期:2014-05-01 00:00:00

  • High-throughput glycosylation analysis of therapeutic immunoglobulin G by capillary gel electrophoresis using a DNA analyzer.

    abstract::The Fc glycosylation of therapeutic antibodies is crucial for their effector functions and their behavior in pharmacokinetics and pharmacodynamics. To monitor the Fc glycosylation in bioprocess development and characterization,high-throughput techniques for glycosylation analysis are needed. Here, we describe the deve...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.26712

    authors: Reusch D,Haberger M,Kailich T,Heidenreich AK,Kampe M,Bulau P,Wuhrer M

    更新日期:2014-01-01 00:00:00

  • Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.

    abstract::The annual "Antibody Industrial Symposium", co organized by LabEx MAbImprove, MabDesign and Polepharma, was held in Tours, France on June 27-28, 2017. The focus was on antibody-drug-conjugates (ADCs), new entities which realize the hope of Paul Ehrlich's magic bullet. ADCs result from the bioconjugation of a highly cy...

    journal_title:mAbs

    pub_type:

    doi:10.1080/19420862.2017.1412130

    authors: Martin C,Kizlik-Masson C,Pèlegrin A,Watier H,Viaud-Massuard MC,Joubert N

    更新日期:2018-02-01 00:00:00

  • Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.

    abstract::Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite significantly enhanced homogeneity, however, the production of site-specific ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1624127

    authors: Cao M,De Mel N,Jiao Y,Howard J,Parthemore C,Korman S,Thompson C,Wendeler M,Liu D

    更新日期:2019-08-01 00:00:00

  • Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.

    abstract::Ch-mAb7F9, a human-mouse chimeric monoclonal antibody (mAb) designed to bind (+)-methamphetamine (METH) with high affinity and specificity, was produced as a treatment medication for METH abuse. In these studies, we present the preclinical characterization that provided predictive evidence that ch-mAb7F9 may be safe a...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.27620

    authors: Stevens MW,Tawney RL,West CM,Kight AD,Henry RL,Owens SM,Gentry WB

    更新日期:2014-03-01 00:00:00

  • Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.

    abstract::Glycosylation is an important post-translational modification during protein production in eukaryotic cells, and it is essential for protein structure, stability, half-life, and biological functions. In this study, we produced various monoclonal antibody (mAb) glycoforms from Chinese hamster ovary (CHO) cells, includi...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.28588

    authors: Zheng K,Yarmarkovich M,Bantog C,Bayer R,Patapoff TW

    更新日期:2014-05-01 00:00:00

  • Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America.

    abstract::Biological therapies have revolutionized the treatment of several cancers and systemic immune-mediated inflammatory conditions. Expiry of patents protecting a number of biologics has provided the opportunity to commercialize highly similar versions, known as biosimilars. Biosimilars are approved by regulatory agencies...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.1080/19420862.2018.1484977

    authors: Scheinberg M,Pineda C,Castañeda-Hernández G,Zarbá JJ,Damião A,Arantes LH Jr,Jacobs I

    更新日期:2018-08-01 00:00:00

  • Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system.

    abstract::We describe protein synthesis, folding and assembly of antibody fragments and full-length aglycosylated antibodies using an Escherichia coli-based open cell-free synthesis (OCFS) system. We use DNA template design and high throughput screening at microliter scale to rapidly optimize production of single-chain Fv (scFv...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.4.2.19202

    authors: Yin G,Garces ED,Yang J,Zhang J,Tran C,Steiner AR,Roos C,Bajad S,Hudak S,Penta K,Zawada J,Pollitt S,Murray CJ

    更新日期:2012-03-01 00:00:00

  • Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs.

    abstract::Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory disease in infants and young children worldwide. Currently, treatment is supportive and no vaccines are available. The use of newborn lambs to model hRSV infection in human infants may provide a valuable tool to assess safety and efficacy o...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1470727

    authors: Larios Mora A,Detalle L,Gallup JM,Van Geelen A,Stohr T,Duprez L,Ackermann MR

    更新日期:2018-07-01 00:00:00

  • A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect.

    abstract::Hepatitis B virus (HBV) produces large (L), middle (M), and small (S) envelope proteins, alternatively referred to as hepatitis B surface antigen (HBsAg). Currently, yeast-derived S protein serves as the preventive vaccine, while hepatitis B immune globulin (HBIG) concentrated from pooled plasma of vaccine recipients ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1134409

    authors: Wang W,Sun L,Li T,Ma Y,Li J,Liu Y,Li M,Wang L,Li C,Xie Y,Wen Y,Liang M,Chen L,Tong S

    更新日期:2016-01-01 00:00:00

  • In vitro and in vivo modifications of recombinant and human IgG antibodies.

    abstract::Tremendous knowledge has been gained in the understanding of various modifications of IgG antibodies, driven mainly by the fact that antibodies are one of the most important groups of therapeutic molecules and because of the development of advanced analytical techniques. Recombinant monoclonal antibody (mAb) therapeut...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.29883

    authors: Liu H,Ponniah G,Zhang HM,Nowak C,Neill A,Gonzalez-Lopez N,Patel R,Cheng G,Kita AZ,Andrien B

    更新日期:2014-01-01 00:00:00

  • Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.

    abstract::In the present study, we conducted a Phase 1 study of a recombinant anti-EGFR monoclonal antibody (CMAB009) that has the same amino acid sequence as cetuximab. The purpose of this study was to evaluate the safety, pharmacokinetics, and potential benefit of CMAB009 in Chinese patients with advanced chemotherapy-resista...

    journal_title:mAbs

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/mabs.3.1.14021

    authors: Wang C,He X,Zhou B,Li J,Li B,Qian W,Hou S,Wang H,Shi Y,Guo Y

    更新日期:2011-01-01 00:00:00

  • Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.

    abstract::Immunoglobulins and T cell receptors (TCRs) share common sequences and structures. With the goal of creating novel bispecific antibodies (BsAbs), we generated chimeric molecules, denoted IgG_TCRs, where the Fv regions of several antibodies were fused to the constant domains of the α/β TCR. Replacing CH1 with Cα and CL...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1007826

    authors: Wu X,Sereno AJ,Huang F,Zhang K,Batt M,Fitchett JR,He D,Rick HL,Conner EM,Demarest SJ

    更新日期:2015-01-01 00:00:00

  • Selection and verification of antibodies against the cytoplasmic domain of M2 of influenza, a transmembrane protein.

    abstract::Interactions between the cytoplasmic domains of viral transmembrane proteins and host machinery often determine the outcome of viral infection. The M2 protein of influenza A has been identified as a key player in autophagy-mediated viral replication. Here, we describe the engineering and validation of an antibody spec...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1843754

    authors: Velappan N,Micheva-Viteva S,Adikari SH,Waldo GS,Lillo AM,Bradbury ARM

    更新日期:2020-01-01 00:00:00

  • A novel human monoclonal antibody specific to the A33 glycoprotein recognizes colorectal cancer and inhibits metastasis.

    abstract::Colorectal cancer represents the second most common cause of cancer-related death. The human A33 transmembrane glycoprotein is a validated tumor-associated antigen, expressed in 95% of primary and metastatic colorectal cancers. Using phage display technology, we generated a human monoclonal antibody (termed A2) specif...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1714371

    authors: Murer P,Plüss L,Neri D

    更新日期:2020-01-01 00:00:00

  • Cell culture processes for monoclonal antibody production.

    abstract::Animal cell culture technology has advanced significantly over the last few decades and is now generally considered a reliable, robust and relatively mature technology. A range of biotherapeutics are currently synthesized using cell culture methods in large scale manufacturing facilities that produce products for both...

    journal_title:mAbs

    pub_type: 杂志文章,评审

    doi:10.4161/mabs.2.5.12720

    authors: Li F,Vijayasankaran N,Shen AY,Kiss R,Amanullah A

    更新日期:2010-09-01 00:00:00

  • Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments.

    abstract::Multispecific antibody formats provide a promising platform for the development of novel therapeutic concepts that could facilitate the generation of safer, more effective pharmaceuticals. However, the production and use of such antibody-based multispecifics is often made complicated by: 1) the instability of the anti...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2016.1248012

    authors: Egan TJ,Diem D,Weldon R,Neumann T,Meyer S,Urech DM

    更新日期:2017-01-01 00:00:00

  • Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

    abstract::Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.25439

    authors: Challa DK,Bussmeyer U,Khan T,Montoyo HP,Bansal P,Ober RJ,Ward ES

    更新日期:2013-09-01 00:00:00

  • Diabody-Ig: a novel platform for the generation of multivalent and multispecific antibody molecules.

    abstract::Multivalent mono- or bispecific antibodies are of increasing interest for therapeutic applications, such as efficient receptor clustering and activation, or dual targeting approaches. Here, we present a novel platform for the generation of Ig-like molecules, designated diabody-Ig (Db-Ig). The antigen-binding site of D...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1603024

    authors: Seifert O,Rau A,Beha N,Richter F,Kontermann RE

    更新日期:2019-07-01 00:00:00

  • Specific and high-resolution identification of monoclonal antibody fragments detected by capillary electrophoresis-sodium dodecyl sulfate using reversed-phase HPLC with top-down mass spectrometry analysis.

    abstract::In recent years, capillary electrophoresis-sodium dodecyl sulfate (cSDS) has been widely used for high resolution separation and quantification of the fragments and aggregates of monoclonal antibodies (mAbs) to ensure the quality of mAb therapeutics. However, identification of the low-molecular-weight (LMW) and high-m...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1646554

    authors: Wang WH,Cheung-Lau J,Chen Y,Lewis M,Tang QM

    更新日期:2019-10-01 00:00:00

  • EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.

    abstract::Bispecific antibody therapeutics can expand the functionality of a conventional monoclonal antibody drug because they can bind multiple antigens. However, their great potential is counterbalanced by the challenges faced in their production. The classic asymmetric bispecific containing an Fc requires the expression of ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1519631

    authors: Cooke HA,Arndt J,Quan C,Shapiro RI,Wen D,Foley S,Vecchi MM,Preyer M

    更新日期:2018-11-01 00:00:00

  • Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit.

    abstract::Blockade of immune checkpoint pathways by programmed cell death protein 1 (PD-1) antibodies has demonstrated broad clinical efficacy against a variety of malignancies. Sintilimab, a highly selective, fully human monoclonal antibody (mAb), blocks the interaction of PD-1 and its ligands and has demonstrated clinical ben...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2019.1654303

    authors: Wang J,Fei K,Jing H,Wu Z,Wu W,Zhou S,Ni H,Chen B,Xiong Y,Liu Y,Peng B,Yu D,Jiang H,Liu J

    更新日期:2019-11-01 00:00:00

  • The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.

    abstract::Accurate measurement and functional characterization of antibody Fc domain N-linked glycans is critical to successful biosimilar development. Here, we describe the application of methods to accurately quantify and characterize the N-linked glycans of 2 IgG1 biosimilars with effector function activity, and show the pot...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2015.1016692

    authors: Brady LJ,Velayudhan J,Visone DB,Daugherty KC,Bartron JL,Coon M,Cornwall C,Hinckley PJ,Connell-Crowley L

    更新日期:2015-01-01 00:00:00

  • Sequencing antibody repertoires: the next generation.

    abstract::Genomic studies have been revolutionized by the use of next generation sequencing (NGS) that delivers huge amounts of sequence information in a short span of time. The number of applications for NGS is rapidly expanding and significantly transforming many areas of life sciences. The field of antibody research and disc...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.4161/mabs.3.1.14169

    authors: Fischer N

    更新日期:2011-01-01 00:00:00

  • Functional domain analysis of SOX18 transcription factor using a single-chain variable fragment-based approach.

    abstract::Antibodies are routinely used to study the activity of transcription factors, using various in vitro and in vivo approaches such as electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, genome-wide method analysis coupled with next generation sequencing, or mass spectrometry. More recently, a new ap...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2018.1451288

    authors: Fontaine FR,Goodall S,Prokop JW,Howard CB,Moustaqil M,Kumble S,Rasicci DT,Osborne GW,Gambin Y,Sierecki E,Jones ML,Zuegg J,Mahler S,Francois M

    更新日期:2018-05-01 00:00:00

  • Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.

    abstract::Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term 'developability' encompasses the feasibility of molecules to successfully progress from discovery to development via evaluation of their physicochemical properties. These properties includ...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1743053

    authors: Bailly M,Mieczkowski C,Juan V,Metwally E,Tomazela D,Baker J,Uchida M,Kofman E,Raoufi F,Motlagh S,Yu Y,Park J,Raghava S,Welsh J,Rauscher M,Raghunathan G,Hsieh M,Chen YL,Nguyen HT,Nguyen N,Cipriano D,Fayadat-Dilma

    更新日期:2020-01-01 00:00:00

  • Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry.

    abstract::Therapeutic monoclonal antibodies (mAbs) are highly complex proteins that must be exhaustively characterized according to the regulatory authorities' recommendations. MAbs display micro-heterogeneity mainly due to their post-translational modifications, but also to their susceptibility to chemical and physical degrada...

    journal_title:mAbs

    pub_type: 杂志文章

    doi:10.1080/19420862.2020.1781743

    authors: Rouby G,Tran NT,Leblanc Y,Taverna M,Bihoreau N

    更新日期:2020-01-01 00:00:00